Gauthier Bernard, Singh Sumeet R, Virani Adil, Staples Heidi, Colbourne Ann
Vision Research (Gauthier), Ottawa.
Can Pharm J (Ott). 2014 Jan;147(1):45-54. doi: 10.1177/1715163513506547.
Several treatment options exist for type 2 diabetes, but little is known about the factors considered by health care providers (HCPs) and patients in Canada in making therapeutic decisions. This study explores perceptions and practices of HCPs and patients related to add-on (i.e., second-line) therapy for type 2 diabetes when initial therapy no longer provides adequate glycemic control.
HCPs (pharmacists, family physicians, diabetes educators, endocrinologists and nurse practitioners) and patients with type 2 diabetes in Ottawa and Halifax were randomly selected to participate in the study. Phone interviews were conducted with endocrinologists and nurse practitioners and focus groups with the other HCPs and patients.
Sixty HCPs and 14 patients participated in the study. Metformin was consistently reported by prescribers (physicians and nurse practitioners) as the preferred initial therapy. Important factors in choosing second-line therapy (once glycemic control was inadequate with metformin) were antihyperglycemic efficacy, risk of hypoglycemia and weight gain, and long-term safety. Other considerations were cost, insurance coverage and patient preference. There were differences within and between HCP groups in how these other factors were considered and in the perceived advantages and disadvantages of each drug class. Some patients expressed anxiety when second-line agents were prescribed, and others felt poorly informed about treatment options.
In choosing a second-line therapy for type 2 diabetes, most HCPs placed a high priority on antihyperglycemic efficacy, although there was considerable variability in the relative weight placed on other factors. These findings point to an opportunity for pharmacists to collaborate more actively with other HCPs to ensure that treatment decisions are based on the best available evidence and to educate and involve patients in these decisions.
2型糖尿病有多种治疗选择,但对于加拿大医疗保健提供者(HCPs)和患者在做出治疗决策时所考虑的因素知之甚少。本研究探讨了当初始治疗不再能充分控制血糖时,HCPs和患者对于2型糖尿病附加(即二线)治疗的看法和做法。
随机选择渥太华和哈利法克斯的HCPs(药剂师、家庭医生、糖尿病教育者、内分泌学家和执业护士)以及2型糖尿病患者参与研究。对内分泌学家和执业护士进行电话访谈,对其他HCPs和患者进行焦点小组访谈。
60名HCPs和14名患者参与了研究。处方医生(医生和执业护士)一致报告二甲双胍是首选的初始治疗药物。选择二线治疗(一旦二甲双胍控制血糖不足)的重要因素是降糖疗效、低血糖风险和体重增加以及长期安全性。其他考虑因素包括成本、保险覆盖范围和患者偏好。在如何考虑这些其他因素以及每种药物类别的感知优势和劣势方面,HCPs组内和组间存在差异。一些患者在开具二线药物时表示焦虑,另一些患者觉得对治疗选择了解不足。
在选择2型糖尿病的二线治疗时,大多数HCPs高度重视降糖疗效,尽管在对其他因素的相对权重上存在相当大的差异。这些发现表明药剂师有机会更积极地与其他HCPs合作,以确保治疗决策基于最佳可用证据,并让患者参与这些决策并接受相关教育。